| 8.81 0.72 (8.9%) | 10-19 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 11.91  |
1-year : | 13.49 |
| Resists | First : | 10.2 |
Second : | 11.55 |
| Pivot price | 8.76 |
|||
| Supports | First : | 8.03 |
Second : | 6.68 |
| MAs | MA(5) : | 8.41 |
MA(20) : | 8.84 |
| MA(100) : | 11.38 |
MA(250) : | 0 | |
| MACD | MACD : | -0.6 |
Signal : | -0.6 |
| %K %D | K(14,3) : | 18.2 |
D(3) : | 12.6 |
| RSI | RSI(14): 44.4 |
|||
| 52-week | High : | 15.28 | Low : | 8.03 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ MOBI ] has closed below upper band by 47.1%. Bollinger Bands are 0% narrower than normal.
| If tomorrow: | Open lower | Open higher |
| High: | 8.89 - 8.95 | 8.95 - 9 |
| Low: | 7.89 - 7.96 | 7.96 - 8.03 |
| Close: | 8.69 - 8.81 | 8.81 - 8.92 |
Mobia Medical, Inc. develops and commercializes neurostimulation medical devices, including implantable systems for stroke rehabilitation and other neurological conditions. The company provides neurostimulation systems and devices that combine vagus nerve stimulation with therapy to address chronic neurological conditions. Its main product, the Vivistim System, is an FDA-approved implantable device designed to aid in the rehabilitation of upper limb motor function in post-stroke patients. The paired VNS platform is used to help patients relearn movements and improve motor deficits, and it is being developed for additional chronic neurologic conditions such as tinnitus. The company supports healthcare professionals, patients, and caregivers with information and resources related to its offerings. The company serves healthcare professionals and organizations involved in stroke rehabilitation and chronic neurological conditions, as well as patients and caregivers within the healthcare sector. The company was founded in 2007 and is based in Austin, Texas.
Fri, 16 Oct 2026
Effective October 15, Myriam J. Curet joins Mobia Medical (MOBI)'s nominating and corporate governance committee. - Stock Titan
Fri, 16 Oct 2026
Audit committee appointee Reza Zadno keeps his compensation committee seat at Mobia Medical (MOBI). - Stock Titan
Tue, 08 Sep 2026
Mobia Medical COO Rawat Prashant B. Executes 15,000 Stock Options at $3.38 Each (NASDAQ: MOBI) - Kalkine Media
Tue, 11 Aug 2026
Mobia Medical Reports Second Quarter 2026 Financial Results - Yahoo Finance
Thu, 14 May 2026
Watkins Represents Mobia Medical in US$150 Million IPO - Latham & Watkins LLP
Wed, 13 May 2026
Mobia IPO Funds Expansion of Stroke Therapy Device - Medical Device and Diagnostic industry
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Specialties
|
|
| Shares Out | 33 (M) |
| Shares Float | 14 (M) |
| Held by Insiders | 19.6 (%) |
| Held by Institutions | 63 (%) |
| Shares Short | 1,080 (K) |
| Shares Short P.Month | 358 (K) |
| EPS | -2.99 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 5.19 |
| Profit Margin | -141.7 % |
| Operating Margin | -132.8 % |
| Return on Assets (ttm) | 0 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 102.4 % |
| Gross Profit (p.s.) | 1.11 |
| Sales Per Share | 1.36 |
| EBITDA (p.s.) | -1.81 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -58 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | -2.96 |
| PEG Ratio | 0 |
| Price to Book value | 1.69 |
| Price to Sales | 6.47 |
| Price to Cash Flow | -5.03 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|